QTTB Latest Press Releases

-- November 11, 2026 --

Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London PRNewswire 6:59 AM

-- November 4, 2026 --

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 6:59 AM

-- September 30, 2026 --

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 PRNewswire 9:15 AM

-- September 21, 2026 --

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 PRNewswire 9:16 AM

-- September 14, 2026 --

Q32 Bio Appoints Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer PRNewswire 6:59 AM

-- September 1, 2026 --

Q32 Bio to Participate in Upcoming September Investor Conferences PRNewswire 7:00 AM

-- August 5, 2026 --

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 6:59 AM

-- July 14, 2026 --

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants PRNewswire 10:59 PM

-- July 13, 2026 --

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PRNewswire 4:01 PM

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PRNewswire 6:59 AM

-- July 10, 2026 --

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 PRNewswire 4:05 PM

Market Data Delayed 15 Minutes